4.5 Review

Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes

Journal

CYTOKINE
Volume 60, Issue 1, Pages 1-12

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.cyto.2012.06.018

Keywords

MCP-1; Inflammation; Obesity; Diabetes; Diabetic complications

Funding

  1. NCCAM [R21 AT003874]
  2. ORWH [R21 AT005139]
  3. RCMI/BRIDGES [5G12RR003061]
  4. RTRN [1J54RR022762]
  5. NCRR [5P2ORR016467]

Ask authors/readers for more resources

monocyte Chemoattractant Protein-1 (MCP-1) is the first discovered and most extensively studied CC chemokine, and the amount of studies on its role in the etiologies of obesity- and diabetes-related diseases have increased exponentially during the past two decades. This review attempted to provide a panoramic perspective of the history, regulatory mechanisms, functions, and therapeutic strategies of this chemokine. The highlights of this review include the roles of MCP-1 in the development of obesity, diabetes, cardiovascular diseases, insulitis, diabetic nephropathy, and diabetic retinopathy. Therapies that specifically or non-specifically inhibit MCP-1 overproduction have been summarized. (C) 2012 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available